A Randomized, Double-blind, Placebo Controlled Study of the Effectiveness of Chronic Incretin-based Therapy on Insulin Secretion in Cystic Fibrosis
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Sitagliptin (Primary)
- Indications Cystic fibrosis; Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 10 Sep 2019 Planned End Date changed from 1 Dec 2018 to 14 Dec 2020.
- 10 Sep 2019 Planned primary completion date changed from 1 Dec 2018 to 14 Dec 2019.
- 10 Sep 2019 Status changed from to active, no longer recruiting.